We are dedicated to providing a new dawn or "eos" for patients with mental health conditions by developing next generation, first- and best-in-class therapies. Over 100 million patients in the United States are affected by neuropsychiatric disorders, with anxiety and substance use disorders among the largest areas of unmet medical need. Our clinical-stage pipeline was licensed from Roche and includes oral small molecules targeting GABAA-γ1, V1a, TAAR1 and GABAA-α5 with broad potential in general anxiety, social anxiety, substance use disorders and cognitive impairment. Newleos was co-founded by Longwood Fund, Federico Bolognani, M.D., Ph.D., and William Martin, Ph.D., seasoned experts in company creation and CNS drug development.
Company Details
- Employees
- 19
- Founded
- -
- Address
- 800 Boylston St,
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- https://newleos.com/
- HQ
- Boston, Massachusetts
Newleos Therapeutics Questions
Newleos Therapeutics's website is https://newleos.com/
Newleos Therapeutics's LinkedIn profile is https://www.linkedin.com/company/newleos-therapeutics
Newleos Therapeutics has
19 employees.
View email and phone details for 19
employees at Newleos Therapeutics.
Newleos Therapeutics's industry is
Biotechnology Research
Newleos Therapeutics's top competitors are
Verdiva Bio,
Abcuro, Inc,
Akero Therapeutics,
Light Horse Therapeutics,
Disc Medicine,
Advancell,
Ascentage Pharma,
Helicore Biopharma,
Timberlyne Therapeutics,
A2 Biotherapeutics, Inc..
Newleos Therapeutics's categories are Biotechnology Research
Newleos Therapeutics's founding year is 2024
